Stay updated on Amivantamab in Esophagogastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.

Latest updates to the Amivantamab in Esophagogastric Cancer Clinical Trial page
- Check5 days agoChange DetectedAdded a government funding notice about NIH operations and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check12 days agoChange DetectedAdded a glossary toggle and updated metadata labels (QC criteria status and FEAR Act data). The page revision was updated to v3.4.0.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4; no substantive content changes to the trial details were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedExpanded and reorganized the study's site information by adding a generic Locations section and listing sites in California, Massachusetts, New Jersey, and New York. The previous state-specific location blocks were removed.SummaryDifference0.6%

- Check69 days agoChange DetectedRevision: v3.3.2 is now displayed on the page, replacing the previous v3.3.1. This appears to be a minor site version update without changes to the study content, eligibility criteria, or outcomes.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision: v3.3.1 replaces the previous Revision: v3.2.0 on the page, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Amivantamab in Esophagogastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.